mild diarrhoea through to life threatening pseudomembranous colitis. Around 20% of patients 23 may suffer recurrent disease which often requires re-hospitalisation of patients.
24
C. difficile was isolated from stool samples from a patient with two recurrent C. difficile 25 infections. PCR-ribotyping, whole genome sequencing and phenotypic assays were used to 26 characterise these isolates.
27
Genotypic and phenotypic screening of C. difficile isolates revealed multiple PCR-ribotypes 28 present, and the emergence of rifamycin resistance during the infection cycle. (2). Recurring CDI not only causes distress to patients, but is also a substantial burden on the 45 healthcare system due to the increased cost (3) associated with possible prolonged stay or re-46 admission of a patient to hospital and the re-administration of diagnostic tests and antibiotics 47 (4). Collaborations between clinicians and researchers are contributing to the knowledge of 48 how both the host and bacterium are affecting recurrent disease, in order to reduce recurrence 49 rates, through personalised patient care regimens (5). 50 In this study multiple stool samples from a patient enrolled in a clinical trial (see case 51 information) were collected and C. difficile was isolated. The strains isolated from these 52 samples were then phenotypically and genotypically characterised to deduce if changes in the 53 C. difficile strain genotype and phenotype could have contributed to recurrent infection.
54

Case
55
A male participant (01008) aged 85 years who had a history of chronic kidney disease and 56 was on multiple long term medication including, bumetanide, candesartan, digoxin, 57 simvastatin, doxazosin, ferrous fumarate and prednisolone. Three months prior to trial 58 enrolment the participant received cefuroxime and gentamicin for a urinary tract infection. 59 One month prior to trial enrolment he was admitted to the hospital, where he received 60 clindamycin (both orally and intravenously) for an infected leg ulcer.
In June 2013, after being re-admitted to hospital, he was diagnosed with CDI (Table 1; 62 sample A), was treated with metronidazole (MET) and discharged. He was diagnosed again 63 with CDI in July (Table 1 ; sample B) and was again treated with MET. 64 In July 2013, within 5 days of cessation of successful treatment of CDI with MET (defined as 65 cessation of diarrhoea for 2 or more days with no loose stools, assessed), he was enrolled on a 66 randomised double blind placebo controlled clinical research trial, aimed at using Rifaximin 67 for reducing relapse of Clostridium associated diarrhoea (RAPID-NCT01670149). A 68 simplified study time line of stool sample collection is outlined in Figure 1 .
69
The participant successfully provided one trial stool sample ( Nottingham, that were proven C. difficile toxin positive by using the C. diff Quik Chek 89 complete kit (Alere) and PCR using the BD MAX™ Cdiff kit (BD Molecular Diagnostics).
90
C. difficile was cultured from ~ 300mg of stool using a previously published protocol (6). 1-91 20 C. difficile colonies were isolated per sample ( was changed to 50% to try and capture as many high quality changes as possible.
144
Results
145
Ribotype of Clostridium difficile Isolates obtained from stool
146
During the course of infection two distinct C. difficile PCR-ribotypes were isolated (Table 2) .
147
The predominant PCR-ribotype occurring during the infection was RT002. Co-infection of 148 the participant with a second PCR-ribotype (RT014), was detected in stool sample E. This Isolate Growth, Sporulation and toxin quantification 156 All isolates showed similar growth profiles in both BHIS and TY (data not shown) except 157 isolate G. This isolate had a shorter stationary phase when grown in BHIS and reduced 158 growth in TY broth. However, this did not affect sporulation and toxin titre as there were no 159 significant differences in these phenotypes, between any of the isolates (data not shown).
160
Pacific Bioscience and Illumina MiSeq Sequencing of RT002 and RT014 isolates 161 The PacBio sequencing was able to assemble the genome of isolate A into four contigs 162 (Table 3 ) and isolate E2 into one contig of 4,330,205bp. Contigs were identified by means of 163 Blast searches using the dc-megablast option against the nt database. BLAST analysis of the 164 one contig from isolate E2 suggests that it shares sequence similarity with the 165 Peptoclostridium difficile genome assembly CD630DERM, chromosome : 1 (LN614756.1).
166
The individual contigs were annotated using RAST (10) and used as reference strains for 167 Illumina read mapping of all isolates. and C, showed complete susceptibility to rifampicin (RIF) and rifaximin (RFX) (Figs. S1a, 209 S1b, S2a & S2b). However, RT002 isolates D (from the relapse sample) and E1 (post relapse 210 sample) showed high resistance (≥ 256 µg/ml) to RIF and RFX (≥128 µg/ml), whilst RT002 211 isolates F and G showed intermediate resistance to both (RIF;≥4 µg/ml, RFX;≥16 µg/ml ).
212
The RT014 isolates (E2 and H) and control strains were fully susceptible to RIF and RFX 213 (>0.5 µg/ml). (Figs. S1a, S1b, S2a & S2b).
214
Frequency of rpoB SNVs in all cultured A to G RT002 isolate samples 215 To try and discern whether there were two distinct populations of RIF and RFX resistant 216 RT002 isolates, the region in rpoB that contained the SNVs identified in Table 4, was   217 amplified from every isolate with a PCR-ribotype banding pattern confirmed with the 218 QIAxcel ( Table 1 ). The PCR amplified DNA fragment was sent for Sanger sequencing and 219 the sequences were checked for the above SNVs. The frequency of these SNVs in each 220 isolate is detailed in Table 5 . Thermus aquaticus directly binds to rifampicin (7, 17 isolates. However, this data may not be representative of in vivo sporulation characteristics; 286 therefore it cannot be conclusively proven that this SNV had no effect. The opp operon is It is poignant to note that other studies have documented cases of C. difficile rifamycin 317 resistance after chaser therapies using rifaximin (8, 22, 23) . One of these studies has linked 318 this resistance to mutations in RpoB (8) that have been identified by others (7). The study by 319 Curry et al. (8) indicates that in their study population, more than one-third of isolates were 320 resistant to rifaximin and this is something which could be looked at in a wider population of 321 participants on the RAPID trial, as it may prompt clinicians to alter dosing regimen if the 322 therapy was approved for use in patients suffering recurrence.
Conclusion
324
This case study has presented insight in to the course of recurrent infection caused by C.
325
difficile. In this case it was difficult to ascertain whether, in this particular individual, the C. 
